Targets › GPR35
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.
G protein-coupled receptor that binds to several ligands including the tryptophan metabolite kynurenic acid (KYNA), lysophosphatidic acid (LPA) or 5-hydroxyindoleacetic acid (5-HIAA) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and…. (UniProt, Q9HC97)
Open in Phaseline: the race on GPR35, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Crossignal Therapeutics | CT3001 GPR35 inhibitor | GPR35 | Phase 1 | Solid Tumor, Adult | Jun 2027 |
Solid Tumor, Adult (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.